Dr. David Reardon on Treating Glioblastoma Patients With EGFRvIII-Mutations
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor.
David Reardon, MD, clinical director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, on the need to identify glioblastoma (GBM) patients with the EGFRvIII mutation in their tumor. Although this mutation is only present in roughly 30% of patients, there is a new treatment, rindopepimut (CDX-110), which has proven to be well tolerated and can improve survival in these patients.
Reardon says it is important for community oncologists to be able to identify GBM patients with this mutation so they can receive the treatment. He says testing to identify that mutation is routinely done at most medical centers.
